Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study
2016
Objective This study prospectively assessed putative promising biomarkers for use in assessing infants with
spinal muscular atrophy(
SMA). Methods This prospective, multi-center
natural history studytargeted the enrollment of
SMAinfants and healthy control infants less than 6 months of age. Recruitment occurred at 14 centers within the NINDS National Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) Network. Infant motor function scales and putative electrophysiological, protein and molecular biomarkers were assessed at baseline and subsequent visits. Results Enrollment began November, 2012 and ended September, 2014 with 26
SMAinfants and 27 healthy infants enrolled. Baseline demographic characteristics of the
SMAand control infant cohorts aligned well. Motor function as assessed by the Test for Infant Motor Performance Items (TIMPSI) and the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) revealed significant differences between the
SMAand control infants at baseline. Ulnar
compound muscle action potentialamplitude (CMAP) in
SMAinfants (1.4 ± 2.2 mV) was significantly reduced compared to controls (5.5 ± 2.0 mV).
Electrical impedance myography(EIM) high-frequency
reactanceslope (Ohms/MHz) was significantly higher in
SMAinfants than controls
SMAinfants had lower survival motor neuron (SMN) mRNA levels in blood than controls, and several serum protein analytes were altered between cohorts. Interpretation By the time infants were recruited and presented for the baseline visit,
SMAinfants had reduced motor function compared to controls. Ulnar CMAP, EIM, blood SMN mRNA levels, and serum protein analytes were able to distinguish between cohorts at the enrollment visit.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
40
References
75
Citations
NaN
KQI